Article navigation

Introduction: Treatment of metastatic urothelial carcinoma (mUC) has evolved. The efficacy of chemotherapy (CT) and immune checkpoint inhibitors (ICIs) against UC with variant differentiation (UC-VD) or pure variant histology (PVH) is rarely reported. This study assessed the clinical impact of first-line (1L) CT and/or ICI in patients with UC-VD or PVH. Methods: This retrospective study included patients treated with 1L palliative CT or ICI at the West German Tumor Center Essen (2006–2024). Treatment allocation reflected real-world clinical decision-making and was not randomized. Primary endpoint was objective response rate (ORR); secondary endpoints were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier analysis, log-rank tests, and descriptive statistics were used. Results: A total of 42 patients were analyzed: 45.2% received ICI (73.6% monotherapy, 26.4% combination/maintenance), 54.8% CT. Median age was 67.7 years in ICI group und 61.2 in CT group. PVH was predominant in CT group (65.2%), while UC-VD with squamous differentiation was common in ICI group (42.1%). ORR of ICI was 52.7%. As secondary endpoints, median PFS and OS were 7.8 months (95% CI: 4.3–19.0) and 12.4 months in ICI group; for CT group, 6.3 months (95% CI: 4.5–11.6), and 10.4 months (95% CI: 1.9–58.2), respectively. ORR was 52.7% (ICI) vs. 39.1% (CT). No significant differences were observed in PFS (p = 0.316), OS (p = 0.318), or ORR (p = 0.515). Conclusions: 1L ICI demonstrated numerically higher response rates compared to 1L CT; however, these results are purely descriptive and serve only to inform hypothesis-building, without reaching statistical significance. Survival outcomes were also better in ICI group, albeit without statistical significance; however, these should be interpreted cautiously given the retrospective design and limited sample size. Given emerging combination strategies involving ICI or targeted agents, these findings support further investigation of ICI in this diverse and underrepresented population. Limitations: This study has small sample size and retrospective design.

1.
Siegel
RL
,
Miller
KD
,
Wagle
NS
,
Jemal
A
.
Cancer statistics, 2023
.
CA Cancer J Clin
.
2023
;
73
(
1
):
17
48
.
2.
Luzzago
S
,
Palumbo
C
,
Rosiello
G
,
Pecoraro
A
,
Deuker
M
,
Tian
Z
, et al
.
The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder
.
J Surg Oncol
.
2019
;
120
(
7
):
1266
75
.
3.
Humphrey
PA
,
Moch
H
,
Cubilla
AL
,
Ulbright
TM
,
Reuter
VE
.
The 2016 WHO classification of tumours of the urinary system and male genital organs: part B – prostate and bladder tumours
.
Eur Urol
.
2016
;
70
(
1
):
106
19
.
4.
Mori
K
,
Abufaraj
M
,
Mostafaei
H
,
Quhal
F
,
Karakiewicz
PI
,
Briganti
A
, et al
.
A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy
.
J Urol
.
2020
;
204
(
6
):
1129
40
.
5.
Liu
Y
.
Urothelial carcinoma with squamous differentiation is associated with high tumor stage and pelvic lymph-node metastasis
.
CA: Los Angeles, CA
:
SAGE Publications Sage
;
2017
.
6.
Royce
TJ
.
Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: results from the National Cancer Data Base
.
Urologic oncology: seminars and original investigations
:
Elsevier
;
2018
.
7.
Minato
A
,
Murooka
K
,
Okumura
Y
,
Takaba
T
,
Higashijima
K
,
Nagata
Y
, et al
.
Efficacy of platinum-based chemotherapy in patients with metastatic urothelial carcinoma with variant histology
.
In Vivo
.
2024
;
38
(
2
):
873
80
.
8.
Kobayashi
M
,
Narita
S
,
Matsui
Y
,
Kanda
S
,
Hidaka
Y
,
Abe
H
, et al
.
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis
.
BJU Int
.
2022
;
130
(
2
):
226
34
.
9.
Bellmunt
J
,
de Wit
R
,
Vaughn
DJ
,
Fradet
Y
,
Lee
JL
,
Fong
L
, et al
.
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
.
N Engl J Med Overseas Ed
.
2017
;
376
(
11
):
1015
26
.
10.
Necchi
A
,
Raggi
D
,
Gallina
A
,
Madison
R
,
Colecchia
M
,
Lucianò
R
, et al
.
Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies
.
Eur Urol
.
2020
;
77
(
4
):
439
46
.
11.
Powles
T
,
Valderrama
BP
,
Gupta
S
,
Bedke
J
,
Kikuchi
E
,
Hoffman-Censits
J
, et al
.
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
.
N Engl J Med
.
2024
;
390
(
10
):
875
88
.
12.
van der Heijden
MS
,
Sonpavde
G
,
Powles
T
,
Necchi
A
,
Burotto
M
,
Schenker
M
, et al
.
Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma
.
N Engl J Med
.
2023
;
389
(
19
):
1778
89
.
13.
Hsieh
MC
,
Sung
MT
,
Chiang
PH
,
Huang
CH
,
Tang
Y
,
Su
YL
.
The prognostic impact of histopathological variants in patients with advanced urothelial carcinoma
.
PLoS One
.
2015
;
10
(
6
):
e0129268
.
14.
McGregor
BA
.
Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH)
;
2019
; p.
4518
.
15.
Minato
A
,
Furubayashi
N
,
Harada
M
,
Negishi
T
,
Sakamoto
N
,
Song
Y
, et al
.
Efficacy of pembrolizumab in patients WithVariant urothelial carcinoma: a multicenter retrospective study
.
Clin Genitourin Cancer
.
2022
;
20
(
5
):
499.e1
8
.
You do not currently have access to this content.
Don't already have an account? Register

Digital Version

Pay-Per-View Access
$45.00
Rental

or Create an Account

Close Modal
Close Modal